Pricing Log in Create free account
Friday 6 November 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

KYMR Healthcare Biotechnology

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Revenue
+466.4%
EPS
−40.3%
Free cash flow
−186.6%
Total debt
−66.6%

Quarter to September 2026, against a year earlier

132.05 3.93 +3.07%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
−31.6×
Dividend yield
—
F-score
4/9
Altman Z
23.22
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Kymera Therapeutics, Inc. 8-K filed Dec 8, 2025

Period ended Dec 8, 2025 · Filed · accepted 7:17 AM ET · Document on sec.gov · Filing index

7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov